Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Rubrik Inc. Class A Common Stock (RBRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Rubrik Inc. Class A Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Rubrik Inc. Class A Common Stock trades at $110.68 (market cap $23.61B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 4.6× Oruka Therapeutics Inc. Common Stock's market cap, and Rubrik Inc. Class A Common Stock is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Rubrik Inc. Class A Common Stock for 4 Days on average.
| ORKA | RBRK | |
|---|---|---|
Market Cap | $5.08B | $23.61B |
Volume | 685,276 | 2,764,516 |
Sector | Health | Technology |
52-Week High | $113.08 | $125.80 |
52-Week Low | $26.19 | $43.81 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $4.21B | $23.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rubrik (RBRK) trades at $118.47, down 1.28% on the day, with strong technical momentum showing bullish moving averages and support at $118. The company demonstrates impressive revenue growth, with 2026 revenue reaching $1.5B and recent earnings beats, though profitability remains negative with a -16.5% net margin. Recent news highlights expansion of AI security offerings including Rubrik Code Guardian and strong institutional buying interest.
Rubrik presents a compelling growth story in cybersecurity with 100% analyst buy ratings and $105.08 consensus target, though current price exceeds this. Key risks include persistent losses despite revenue growth and competitive AI security landscape. The stock's technical strength and AI-driven demand create upside potential, but profitability concerns warrant careful monitoring of margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Rubrik Inc. Class A Common Stock
Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →
